COA Versus Chromatogram: What Each Record Proves

A vial label and a purity figure can look reassuring, but neither tells the full story on its own. The practical question in a COA versus chromatogram review is not which document is better. It is whether the records relate to the same batch, use an appropriate method, and provide enough information for a researcher to judge the material critically.

For research-use peptide materials, documentation is part of quality evaluation rather than an administrative extra. A certificate of analysis, commonly called a COA, presents reported test results against a defined specification. A chromatogram is a visual output from an analytical run, often high-performance liquid chromatography (HPLC). They are connected, but they answer different questions.

COA versus chromatogram: the essential distinction

A COA is a formal batch document. It usually identifies the material, batch or lot number, stated quantity, test methods, acceptance criteria and reported results. Depending on the supplier and analytical scope, it may also include peptide content, chromatographic purity, moisture, residual solvents, identity testing or microbiological results. The level of detail varies considerably.

A chromatogram is the plotted detector response generated as components pass through a chromatography system over time. In an HPLC purity test, the instrument separates compounds according to their interaction with the column and mobile phase. The chart commonly shows retention time on the horizontal axis and detector response on the vertical axis. Peaks represent detected components, while the area under each peak may be used to estimate relative composition.

In simple terms, the COA states the laboratory's reported conclusion. The chromatogram provides some of the underlying visual evidence for one analytical measurement. A COA might report 98% HPLC purity; the associated chromatogram should show how that purity figure was derived. Yet a chromatogram without context is not automatically proof of identity, and a COA without traceable batch details is difficult to evaluate.

What a useful certificate of analysis should contain

A credible COA allows the reader to connect the report to a specific material and understand what was tested. At minimum, look for a clear product or compound name, a batch or lot number, report date, testing laboratory or quality-control function, method reference, result and specification.

The batch number deserves particular attention. It should correspond to the number shown on the vial or outer label. If the physical label and documentation do not match, the report may relate to another production run, even if the compound name is the same. Batch-specific records are more informative than a generic sample document reused across multiple lots.

Method language matters as well. “Purity: 99%” is less useful than “HPLC purity: 99.0% by area normalisation”, because the latter identifies the technique and calculation basis. Area normalisation means each detected peak area is expressed as a proportion of the total integrated peak area. It is widely used for comparative purity assessment, but it does not necessarily measure the absolute mass of every impurity with equal accuracy.

A COA may also list mass spectrometry results. For peptides, mass spectrometry can support confirmation that a signal consistent with the expected molecular mass is present. This adds a different kind of evidence to HPLC. HPLC assesses separation and relative purity under a stated method; mass spectrometry assesses mass-to-charge characteristics. Neither should be described as a complete guarantee of peptide sequence, sterility or suitability for any human application.

Other entries, such as water content or residual solvent testing, can be meaningful where they are relevant to the material and method. Their absence does not automatically indicate poor quality, but it does define what the document does and does not establish.

How to read an HPLC chromatogram

The most visible feature of a chromatogram is normally the main peak. If a peptide is reported as highly pure by HPLC, the principal peak will often account for most of the integrated area. Smaller peaks can indicate impurities, related compounds, degradation products, solvents or other components detected at the selected wavelength.

A clean-looking trace still needs interpretation. The retention time of the main peak should be stated or readily inferable, and the report should identify the detector, commonly UV detection at a specified wavelength. Peptides absorb differently depending on their amino-acid composition, so detector settings affect what is observed. A trace recorded at one wavelength may not reveal every possible impurity equally well.

Peak integration is another consideration. Analytical software calculates peak areas using defined start and end points, baselines and integration rules. Poor integration can exaggerate or minimise apparent minor peaks. For that reason, a chart image without a peak table, method conditions or integration details offers limited analytical confidence.

The best chromatograms are legible and accompanied by enough context to be assessed: sample identifier, run date, column type, mobile phases, gradient, flow rate, detection wavelength and peak-area table. A full method is not always supplied in consumer-facing documentation, particularly where laboratory procedures are proprietary, but the more clearly the report identifies the test, the more meaningful its result becomes.

Why a high purity percentage is not the whole quality picture

HPLC purity is useful, but it is a narrow measurement. It estimates the proportion of chromatographically detected material represented by the principal peak under one set of conditions. It does not, by itself, establish peptide sequence, biological activity, concentration after reconstitution, sterility, endotoxin level or the absence of all contaminants.

This is especially relevant for peptide compounds because some related impurities may elute close to the target peak, or may have limited response at the selected detector wavelength. Co-elution occurs when different components emerge from the column at approximately the same time, appearing as one peak. Method development is intended to reduce this risk, but no single screening result should be stretched beyond what it can show.

Identity is similarly distinct from purity. A material can have a single dominant peak and still require orthogonal testing, such as mass spectrometry, for stronger identity support. Conversely, a mass result consistent with the expected molecular mass does not quantify chromatographic purity. Thoughtful quality review considers the tests as complementary evidence rather than interchangeable badges.

A practical way to assess the documents together

Begin with traceability. Check that the compound name, batch number and report date are consistent across the vial, COA and chromatogram. Next, identify what result is actually being reported. Is it HPLC area purity, peptide content, identity confirmation or something else? Similar wording can describe different tests.

Then compare the COA result with the chromatogram. If the COA reports 98% HPLC purity, the peak table should broadly support a main peak comprising about 98% of total integrated area. A small discrepancy may arise from rounding or presentation, but a substantial mismatch deserves clarification.

Finally, consider the limits of the evidence. A batch-specific COA paired with a dated HPLC trace and identity data is more informative than a percentage printed on a label. Even so, documentation should support informed research evaluation, not replace independent verification where a project requires a defined analytical standard.

Common documentation weaknesses

Several patterns warrant a cautious response. A generic COA with no batch number cannot be confidently tied to a particular vial. A chromatogram with the axes cropped, no sample identification or no peak table may be visually persuasive but analytically thin. A report that only states “tested” without naming the method leaves the result difficult to interpret.

It is also sensible to distinguish between a certificate issued by a supplier and an independent third-party report. Both can contain useful information, but independent testing may provide added separation between production and verification. The key point is transparency about who performed the analysis, when it was performed and which batch was tested.

For researchers reviewing peptide documentation through Regena Peptides or any other source, clarity is preferable to broad assurances. Ask whether the available records are batch-specific, whether the methods are identified and whether the stated claims remain within the scope of the test.

Documentation supports better research decisions

A COA and chromatogram are most valuable when treated as a connected evidence set. The COA supplies the formal record, specification and reported conclusion. The chromatogram offers a view of the separation behind a purity result. Neither document should be expected to answer every question about a research material.

The useful habit is to read each report with precision: match the lot, identify the method, understand the percentage and recognise the test’s limits. That approach makes quality documentation more than a marketing attachment. It becomes a practical part of reproducible, carefully considered research.